Alembic Pharmaceuticals has informed the exchange that the Company has received US Food & Drug Administration (USFDA) Final Approval for Prazosin Hydrochloride Capsules USP, 1 mg, 2 mg, and 5 mg. In this regard, the company has enclosed its press release.
The above information is a part of company’s filings submitted to BSE.